Fidelity Investments’s Processa Pharmaceuticals PCSA Stock Holding History

Fidelity Investments’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10	Buy	+6	New	+$13	﹤0.01%	5716

Other funds holding PCSA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $273B AUM 15.34% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Fidelity Investments's PCSA Position: Q3 2026 in Review

Fidelity Investments opened a new position in Processa Pharmaceuticals (PCSA) in Q3 2026: 6 shares worth $10. The stake represents ﹤0.01% of the portfolio and ranks #5716 among its holdings.

9 funds tracked by Wall St. Rank hold PCSA as of Q3 2026.

Fidelity Investments held 6 shares of Processa Pharmaceuticals worth $10 as of Q3 2026.
Processa Pharmaceuticals was a new Fidelity Investments position in Q3 2026.
Processa Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #5716 holding.
9 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.